Drug Information

Drug General Information
Drug ID
D01PIL
Former ID
DAP000312
Drug Name
Remoxipride
Synonyms
Remoxiprida; Remoxipridum; Romoxipride; A 33547; FLA 731; A-33547; FLA-731; Remoxiprida [INN-Spanish]; Remoxipride (USAN); Remoxipridum [INN-Latin]; Remoxipride [USAN:BAN:INN]; (-)-(S)-3-Brom-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamid; (-)-(S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; (-)-n-ethyl-2-(3-bromo-2,6-dimethoxybenzamidomethyl)pyrrolidine; (S)-3-Bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; (S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Withdrawn from market [526174]
Therapeutic Class
Antipsychotic Agents
Structure
Download
2D MOL

3D MOL
Formula
C16H23BrN2O3
Canonical SMILES
CCN1CCCC1CNC(=O)C2=C(C=CC(=C2OC)Br)OC
InChI
1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
InChIKey
GUJRSXAPGDDABA-NSHDSACASA-N
CAS Number
CAS 80125-14-0
PubChem Compound ID
54477
PubChem Substance ID
7980506, 8183659, 11112836, 11113786, 11466999, 11468119, 11486648, 12012970, 14755372, 17396851, 26751966, 34718458, 46508689, 47425546, 47425547, 47721872, 47945090, 47945091, 48095783, 49699324, 49875811, 50104640, 50409168, 57313624, 85788347, 85788802, 92308915, 99381443, 103189253, 103935779, 104304992, 117389433, 124886955, 126671568, 128007637, 134337624, 135014299, 137001507, 137263915, 144204485, 160963755, 163693566, 163853023, 170466425, 172860811, 176484143, 179151044, 198968595, 223541941, 223682010
SuperDrug ATC ID
N05AL04
SuperDrug CAS ID
cas=080125140
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Antagonist [535384], [537966]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 526174Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist. CNS Drug Rev. 2001 Fall;7(3):265-82.
Ref 535384Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
Ref 537966Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.